dc.contributor.author | Brand, D | |
dc.contributor.author | Parker, C | |
dc.date.accessioned | 2018-01-24T14:35:20Z | |
dc.date.issued | 2018-04-01 | |
dc.identifier.citation | European urology, 2018, 73 (4), pp. 521 - 523 | |
dc.identifier.issn | 0302-2838 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1021 | |
dc.identifier.eissn | 1873-7560 | |
dc.identifier.doi | 10.1016/j.eururo.2017.12.021 | |
dc.description.abstract | In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel. | |
dc.format | Print-Electronic | |
dc.format.extent | 521 - 523 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Androgen Antagonists | |
dc.subject | Prostate-Specific Antigen | |
dc.subject | Radiotherapy | |
dc.subject | Prostatectomy | |
dc.subject | Risk Assessment | |
dc.subject | Survival Analysis | |
dc.subject | Quality of Life | |
dc.subject | Male | |
dc.subject | Time-to-Treatment | |
dc.subject | Clinical Decision-Making | |
dc.title | Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-12-18 | |
rioxxterms.versionofrecord | 10.1016/j.eururo.2017.12.021 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European urology | |
pubs.issue | 4 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/17/18 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/17/18 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 73 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Stereotactic and Precision Body Radiotherapy | |
dc.contributor.icrauthor | Brand, Douglas | |